Prävention gastrointestinaler Tumore

Zusammenfassung

In den letzten Dekaden wurden erhebliche Fortschritte bei der (frühzeitigen) Diagnostik und Therapie gastrointestinaler onkologischer Erkrankungen erzielt. Allerdings bleibt die Prognose für fortgeschrittene Stadien von gastrointestinalen Tumoren für viele Patienten limitiert, und ungefähr ein Drittel aller Tumorpatienten verstirbt an den Folgen eines gastrointestinalen Tumors. Der Prävention und Früherkennung gastrointestinaler Tumoren kommt somit eine große Bedeutung zu.

Aus diesem Grund fassen wir im Folgenden den Wissensstand und Empfehlungen zur primären, sekundären und tertiären Prävention von Ösophagus-, Magen-, Pankreas-, Leberzell- und kolorektalem Karzinom zusammen.

Abstract

Throughout the past decades, considerable progress has been made in the (early) diagnosis and treatment of gastrointestinal cancers. However, the prognosis for advanced stages of gastrointestinal tumors remains limited for many patients and approximately one third of all tumor patients die as a result of gastrointestinal tumors. The prevention and early detection of gastrointestinal tumors is therefore of great importance.

For this reason, we summarize the current state of knowledge and recommendations for the primary, secondary and tertiary prevention of esophageal, stomach, pancreas, liver and colorectal cancer in the following.

Schlüsselwörter

Gastrointestinale Tumoren - Prävention - Früherkennung - Ösophaguskarzinom - Magenkarzinom

Keywords

Gastrointestinal cancer - prevention - early diagnosis - esophageal cancer - gastric cancer

Publication History

Received: 12 January 2021

Accepted after revision: 25 June 2021

Article published online:
10 September 2021

• Literatur

• 1 Pox CP, Altenhofen L, Brenner H. et al. Efficacy of a nationwide screening colonoscopy program for colorectal cancer. Gastroenterology 2012; 142: 1460-1467 e1462
• 2 Hoffmeister M, Holleczek B, Zwink N. et al. Screening for Bowel Cancer: Increasing Participation via Personal Invitation. Dtsch Arztebl Int 2017; 114: 87-93
• 3 Ferlay J, Soerjomataram I, Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-386
• 4 Hongo M, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol 2009; 24: 729-735
• 5 Cheung WY, Liu G. Genetic variations in esophageal cancer risk and prognosis. Gastroenterol Clin North Am 2009; 38: 75-91
• 6 Codipilly DC, Qin Y, Dawsey SM. et al. Screening for esophageal squamous cell carcinoma: recent advances. Gastrointest Endosc 2018; 88: 413-426
• 7 Taylor PR, Abnet CC, Dawsey SM. Squamous dysplasia – the precursor lesion for esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2013; 22: 540-552
• 8 Cancer Genome Atlas Research N, Analysis Working Group: Asan U, Agency BCC. et al. Integrated genomic characterization of oesophageal carcinoma. Nature 2017; 541: 169-175
• 9 Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease?. Semin Radiat Oncol 2007; 17: 38-44
• 10 Abnet CC, Arnold M, Wei WQ. Epidemiology of Esophageal Squamous Cell Carcinoma. Gastroenterology 2018; 154: 360-373
• 11 Brown LM, Devesa SS, Chow WH. Incidence of Adenocarcinoma of the Esophagus Among White Americans by Sex, Stage, and Age. JNCI Journal of the National Cancer Institute 2008; 100: 1184-1187
• 12 Dong J, Thrift AP. Alcohol, smoking and risk of oesophago-gastric cancer. Best practice & research Clinical gastroenterology 2017; 31: 509-517
• 13 Hyland PL, Zhang H, Yang Q. et al. Pathway, in silico and tissue-specific expression quantitative analyses of oesophageal squamous cell carcinoma genome-wide association studies data. Int J Epidemiol 2016; 45: 206-220
• 14 Tran GD, Sun XD, Abnet CC. et al. Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer 2005; 113: 456-463
• 15 Zeng H, Zheng R, Zhang S. et al. Esophageal cancer statistics in China, 2011: Estimates based on 177 cancer registries. Thorac Cancer 2016; 7: 232-237
• 16 He Y, Li D, Shan B. et al. Incidence and mortality of esophagus cancer in China, 2008–2012. Chin J Cancer Res 2019; 31: 426-434
• 17 Wei WQ, Abnet CC, Lu N. et al. Risk factors for oesophageal squamous dysplasia in adult inhabitants of a high risk region of China. Gut 2005; 54: 759-763
• 18 El-Zimaity H, Di Pilato V, Novella Ringressi M. et al. Risk factors for esophageal cancer: emphasis on infectious agents. Ann N Y Acad Sci 2018; 1434: 319-332
• 19 Liyanage SS, Rahman B, Ridda I. et al. The aetiological role of human papillomavirus in oesophageal squamous cell carcinoma: a meta-analysis. PLoS One 2013; 8: e69238
• 20 Ojesina AI, Lichtenstein L, Freeman SS. et al. Landscape of genomic alterations in cervical carcinomas. Nature 2014; 506: 371-375
• 21 Kunzmann AT, Graham S, McShane CM. et al. The prevalence of viral agents in esophageal adenocarcinoma and Barrett’s esophagus: a systematic review. Eur J Gastroenterol Hepatol 2017; 29: 817-825
• 22 Kawasaki M, Ikeda Y, Ikeda E. et al. Oral infectious bacteria in dental plaque and saliva as risk factors in patients with esophageal cancer. Cancer 2020;
• 23 Li D, He R, Hou G. et al. Characterization of the Esophageal Microbiota and Prediction of the Metabolic Pathways Involved in Esophageal Cancer. Front Cell Infect Microbiol 2020; 10: 268
• 24 Howel-Evans W, Mc CR, Clarke CA. et al. Carcinoma of the oesophagus with keratosis palmaris et plantaris (tylosis): a study of two families. Q J Med 1958; 27: 413-429
• 25 Blaydon DC, Etheridge SL, Risk JM. et al. RHBDF2 mutations are associated with tylosis, a familial esophageal cancer syndrome. Am J Hum Genet 2012; 90: 340-346
• 26 Song Y, Li L, Ou Y. et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature 2014; 509: 91-95
• 27 Abnet CC, Freedman ND, Hu N. et al. A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. Nat Genet 2010; 42: 764-767
• 28 Wang LD, Zhou FY, Li XM. et al. Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54. Nat Genet 2010; 42: 759-763
• 29 Wu C, Hu Z, He Z. et al. Genome-wide association study identifies three new susceptibility loci for esophageal squamous-cell carcinoma in Chinese populations. Nat Genet 2011; 43: 679-684
• 30 Wu C, Wang Z, Song X. et al. Joint analysis of three genome-wide association studies of esophageal squamous cell carcinoma in Chinese populations. Nat Genet 2014; 46: 1001-1006
• 31 Liang H, Fan JH, Qiao YL. Epidemiology, etiology, and prevention of esophageal squamous cell carcinoma in China. Cancer Biol Med 2017; 14: 33-41
• 32 Li XC, Wang MY, Yang M. et al. A mutational signature associated with alcohol consumption and prognostically significantly mutated driver genes in esophageal squamous cell carcinoma. Ann Oncol 2018; 29: 938-944
• 33 Yang X, Zhu H, Qin Q. et al. Genetic variants and risk of esophageal squamous cell carcinoma: a GWAS-based pathway analysis. Gene 2015; 556: 149-152
• 34 Wei WQ, Chen ZF, He YT. et al. Long-Term Follow-Up of a Community Assignment, One-Time Endoscopic Screening Study of Esophageal Cancer in China. J Clin Oncol 2015; 33: 1951-1957
• 35 Wang JW, Guan CT, Wang LL. et al. Natural History Analysis of 101 Severe Dysplasia and Esophageal Carcinoma Cases by Endoscopy. Gastroenterol Res Pract 2017; 2017: 9612854
• 36 Gockel I, Hoffmeister A. Endoscopic or Surgical Resection for Gastro-Esophageal Cancer. Dtsch Arztebl Int 2018; 115: 513-519
• 37 Fitzgerald RC, di Pietro M, O’Donovan M. et al. Cytosponge-trefoil factor 3 versus usual care to identify Barrett’s oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial. Lancet 2020; 396: 333-344
• 38 Murphy G, McCormack V, Abedi-Ardekani B. et al. International cancer seminars: a focus on esophageal squamous cell carcinoma. Ann Oncol 2017; 28: 2086-2093
• 39 Iyer PG, Taylor WR, Johnson ML. et al. Accurate Nonendoscopic Detection of Barrett’s Esophagus by Methylated DNA Markers: A Multisite Case Control Study. Am J Gastroenterol 2020; 115: 1201-1209
• 40 Porschen R, Fischbach W, Gockel I. et al. S3-Leitlinie – Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus. Gastroenterol 2019; 57: 336-418
• 41 Steinberg J, Schwertner C, de Villiers EM. et al. Coincidental squamous cell cancers of the esophagus and head and neck: risk and surveillance. Z Gastroenterol 2007; 45: 710-714
• 42 Abate E, DeMeester SR, Zehetner J. et al. Recurrence after esophagectomy for adenocarcinoma: defining optimal follow-up intervals and testing. J Am Coll Surg 2010; 210: 428-435
• 43 Mantziari S, Allemann P, Dayer A. et al. Gastroesophageal cancer: an update on diagnosis and treatment. Rev Med Suisse 2014; 10: 1331-1336
• 44 Fitzgerald RC, di Pietro M, Ragunath K. et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut 2013;
• 45 Amadi C, Gatenby P. Barrett’s oesophagus: Current controversies. World J Gastroenterol 2017; 23: 5051-5067
• 46 Kunze B, Wein F, Fang HY. et al. Notch Signaling Mediates Differentiation in Barrett’s Esophagus and Promotes Progression to Adenocarcinoma. Gastroenterology 2020; 159: 575-590
• 47 Shaheen N, Ransohoff DF. Gastroesophageal Reflux, Barrett Esophagus, and Esophageal Cancer: Scientific Review. JAMA 2002; 287: 1972
• 48 Falk GW. Barrett’s esophagus. Gastroenterology 2002; 122: 1569-1591
• 49 Verbeek RE, Leenders M, Ten Kate FJ. et al. Surveillance of Barrett’s esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study. The American journal of gastroenterology 2014; 109: 1215-1222
• 50 Shaheen NJ, Richter JE. Barrett’s oesophagus. The Lancet 2009; 373: 850-861
• 51 Vaughan TL, Fitzgerald RC. Precision prevention of oesophageal adenocarcinoma. Nat Rev Gastroenterol Hepatol 2015; 12: 243-248
• 52 Fan X, Snyder N. Prevalence of Barrett’s Esophagus in Patients with or without GERD Symptoms: Role of Race, Age, and Gender. Digestive Diseases and Sciences 2009; 54: 572-577
• 53 Rubenstein JH, Thrift AP. Risk factors and populations at risk: Selection of patients for screening for Barrett’s oesophagus. Best Practice & Research Clinical Gastroenterology 2015; 29: 41-50
• 54 Kabat GC, Ng SKC, Wynder EL. Tobacco, alcohol intake, and diet in relation to adenocarcinoma of the esophagus and gastric cardia. Cancer Causes and Control 1993; 4: 123-132
• 55 Chow WH, Blaser MJ, Blot WJ. et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 1998; 58: 588-590
• 56 Masclee GMC, Coloma PM, Spaander MCW. et al. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett’s oesophagus: a population-based case-control study. BMJ open 2015; 5: e006640-e006640
• 57 Schmidt M, Ankerst DP, Chen Y. et al. Epidemiologic Risk Factors in a Comparison of a Barrett Esophagus Registry (BarrettNET) and a Case–Control Population in Germany. Cancer Prevention Research 2020; 13: 377-384
• 58 Fan X, Snyder N. Prevalence of Barrett’s esophagus in patients with or without GERD symptoms: role of race, age, and gender. Dig Dis Sci 2009; 54: 572-577
• 59 Shaheen N, Ransohoff DF. Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review. Jama 2002; 287: 1972-1981
• 60 Schmidt M, Ankerst DP, Chen Y. et al. Epidemiological risk factors in a comparison of a Barrett Esophagus Registry (BarretNET) and a case control population in Germany. Cancer Prev Res (Phila) 2020;
• 61 Rubenstein JH, Thrift AP. Risk factors and populations at risk: selection of patients for screening for Barrett’s oesophagus. Best practice & research Clinical gastroenterology 2015; 29: 41-50
• 62 Verbeek RE, Leenders M, ten Kate FJW. et al. Surveillance of Barrettʼs Esophagus and Mortality from Esophageal Adenocarcinoma: A Population-Based Cohort Study. American Journal of Gastroenterology 2014; 109: 1215-1222
• 63 Association AG. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology 2011; 140: 1084-1091
• 64 Shaheen NJ, Richter JE. Barrett’s oesophagus. The Lancet 2009; 373: 850-861
• 65 Chiba N, De Gara C, Wilkinson J. et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 1997; 112: 1798-1810
• 66 Hvid-Jensen F, Pedersen L, Funch-Jensen P. et al. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett’s oesophagus: a nationwide study of 9883 patients. Alimentary pharmacology & therapeutics 2014; 39: 984-991
• 67 Koop H, Klein M, Arnold R. Serum gastrin levels during long-term omeprazole treatment. Alimentary pharmacology & therapeutics 2007; 4: 131-138
• 68 Amir I, Konikoff FM, Oppenheim M. et al. Gastric microbiota is altered in oesophagitis and Barrett’s oesophagus and further modified by proton pump inhibitors: Microbiota in oesophageal diseases and PPI therapy. Environmental Microbiology 2014; 16: 2905-2914
• 69 Brusselaers N, Engstrand L, Lagergren J. Maintenance proton pump inhibition therapy and risk of oesophageal cancer. Cancer Epidemiology 2018; 53: 172-177
• 70 Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513: 202-209
• 71 Sugano K, Tack J, Kuipers EJ. et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64: 1353-1367
• 72 Hooi JKY, Lai WY, Ng WK. et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology 2017; 153: 420-429
• 73 Wex T, Venerito M, Kreutzer J. et al. Serological Prevalence of Helicobacter pylori Infection in Saxony-Anhalt, Germany, in 2010. Clinical and Vaccine Immunology 2011; 18: 2109-2112
• 74 Correa P, Houghton J. Carcinogenesis of Helicobacter pylori. Gastroenterology 2007; 133: 659-672
• 75 Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol 1995; 19: S37-43
• 76 Dinis-Ribeiro M, Areia M, de Vries A. et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012; 44: 74-94
• 77 Rugge M, Genta RM. Staging Gastritis: An International Proposal. Gastroenterology 2005; 129: 1807-1808
• 78 Rugge M, Meggio A, Pennelli G. et al. Gastritis staging in clinical practice: the OLGA staging system. Gut 2007; 56: 631-636
• 79 Kwok T, Zabler D, Urman S. et al. Helicobacter exploits integrin for type IV secretion and kinase activation. Nature 2007; 449: 862-866
• 80 Backert S, Haas R, Gerhard M. et al. The Helicobacter pylori Type IV Secretion System Encoded by the cag Pathogenicity Island: Architecture, Function, and Signaling. In: Backert S, Grohmann E. Type IV Secretion in Gram-Negative and Gram-Positive Bacteria. Cham: Springer International Publishing; 2017.
• 81 Helicobacter, Cancer Collaborative G. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001; 49: 347-353
• 82 Ferreira RM, Machado JC, Leite M. et al. The number of Helicobacter pylori CagA EPIYA C tyrosine phosphorylation motifs influences the pattern of gastritis and the development of gastric carcinoma: EPIYA C in gastritis and gastric carcinoma. Histopathology 2012; 60: 992-998
• 83 Hatakeyama M. Helicobacter pylori CagA and Gastric Cancer: A Paradigm for Hit-and-Run Carcinogenesis. Cell Host & Microbe 2014; 15: 306-316
• 84 Höcker M, Hohenberger P. Helicobacter pylori virulence factors—one part of a big picture. The Lancet 2003; 362: 1231-1233
• 85 Oliveira C, Pinheiro H, Figueiredo J. et al. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. The Lancet Oncology 2015; 16: e60-e70
• 86 Yaghoobi M, McNabb-Baltar J, Bijarchi R. et al. What is the quantitative risk of gastric cancer in the first-degree relatives of patients? A meta-analysis. World Journal of Gastroenterology 2017; 23: 2435
• 87 Venerito M, Vasapolli R, Malfertheiner P. Helicobacter pylori and Gastric Cancer: Timing and Impact of Preventive Measures. In: Jansen M, Wright NA. Stem Cells, Pre-neoplasia, and Early Cancer of the Upper Gastrointestinal Tract. Cham: Springer International Publishing; 2016
• 88 Bornschein J, Malfertheiner P. Helicobacter pylori and Gastric Cancer. Digestive Diseases 2014; 32: 249-264
• 89 Wong BC-Y, Lam SK, Wong WM. et al. Helicobacter pylori Eradication to Prevent Gastric Cancer in a High-Risk Region of China: A Randomized Controlled Trial. JAMA 2004; 291: 187
• 90 Lee Y-C, Chiang T-H, Chou C-K. et al. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology 2016; 150: 1113-1124.e1115
• 91 Chen H-N, Wang Z, Li X. et al. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer 2016; 19: 166-175
• 92 Rokkas T. A systematic review and meta-analysis of the role of Helicobacter pylori eradication in preventing gastric cancer. http://www.annalsgastro.gr/files/journals/1/earlyview/2017/ev-04–2017–05-AG2997–0144.pdf. Annals of Gastroenterology 2017.
• 93 Pan K-f, Zhang L, Gerhard M. et al. A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication. Gut 2016; 65: 9-18
• 94 Lee Y-C, Chen TH-H, Chiu H-M. et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut 2013; 62: 676-682
• 95 Choi IJ, Kim CG, Lee JY. et al. Family History of Gastric Cancer and Helicobacter pylori Treatment. New England Journal of Medicine 2020; 382: 427-436
• 96 Moehler M, Al-Batran SE, Andus T. et al. S3-Leitlinie Magenkarzinom – Diagnostik und Therapie der Adenokarzinome des Magens und des ösophagogastralen Übergangs – Langversion 2.0 – August 2019. AWMF-Registernummer: 032/009OL. Z Gastroenterol 2019; 57: 1517-1632
• 97 Moehler M, Langer T, Bender T. et al. Leitlinienreport zur S3-Leitlinie Magenkarzinom – „Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs“: Version 2.0 – August 2019 – AWMF-Registernummer: 032/009OL. Zeitschrift für Gastroenterologie 2019; 57: e418-e671
• 98 Malfertheiner P, Megraud F, O’Morain CA. et al. Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646-664
• 99 Selgrad M, Bornschein J, Kandulski A. et al. Combined Gastric and Colorectal Cancer Screening-A New Strategy. Int J Mol Sci 2018; 19
• 100 Planade O, Dessomme B, Chapelle N. et al. Systematic upper endoscopy concomitant with colonoscopy performed within the colorectal cancer screening program: Impact on the patients’ management. Clin Res Hepatol Gastroenterol 2021; 45: 101501
• 101 Pimentel-Nunes P, Libânio D, Marcos-Pinto R. et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy 2019; 51: 365-388
• 102 Dixon MF, Genta RM, Yardley JH. et al. Classification and Grading of Gastritis: The Updated Sydney System. The American Journal of Surgical Pathology 1996; 20: 1161-1181
• 103 Gotoda T, Iwasaki M, Kusano C. et al. Endoscopic resection of early gastric cancer treated by guideline and expanded National Cancer Centre criteria. Br J Surg 2010; 97: 868-871
• 104 Ono H, Yao K, Fujishiro M. et al. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer. Dig Endosc 2016; 28: 3-15
• 105 Choi IJ, Kook M-C, Kim Y-. et al. Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer. New England Journal of Medicine 2018; 378: 1085-1095
• 106 Fattovich G, Stroffolini T, Zagni I. et al. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 2004; 127: S35-S50
• 107 El-Serag HB. Hepatocellular Carcinoma. New England Journal of Medicine 2011; 365: 1118-1127
• 108 Mancebo A, González-Diéguez ML, Cadahía V. et al. Annual Incidence of Hepatocellular Carcinoma Among Patients With Alcoholic Cirrhosis and Identification of Risk Groups. Clinical Gastroenterology and Hepatology 2013; 11: 95-101
• 109 Yang JD, Kim WR, Coelho R. et al. Cirrhosis Is Present in Most Patients With Hepatitis B and Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology 2011; 9: 64-70
• 110 Paradis V, Zalinski S, Chelbi E. et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: A pathological analysis. Hepatology 2009; 49: 851-859
• 111 Yasui K, Hashimoto E, Komorizono Y. et al. Characteristics of Patients With Nonalcoholic Steatohepatitis Who Develop Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology 2011; 9: 428-433
• 112 Chang M-H, Chen C-J, Lai M-S. et al. Universal Hepatitis B Vaccination in Taiwan and the Incidence of Hepatocellular Carcinoma in Children. New England Journal of Medicine 1997; 336: 1855-1859
• 113 Kao JH. Hepatitis B vaccination and prevention of hepatocellular carcinoma. Best practice & research Clinical gastroenterology 2015; 29: 907-917
• 114 Asia-Pacific Working Party on Prevention of Hepatocellular C. Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. J Gastroenterol Hepatol 2010; 25: 657-663
• 115 Choi WM, Kim HJ, Ko MJ. et al. AASLD The Liver Meeting Digital Experience, November 13–16, 2020. Abstract 137. AASLD The Liver Meeting Digital. Experience, November 13–16. 2020 Abstract 137. 2020
• 116 Hwang IC, Chang J, Kim K. et al. Aspirin Use and Risk of Hepatocellular Carcinoma in a National Cohort Study of Korean Adults. Sci Rep 2018; 8: 4968
• 117 Lee TY, Hsu YC, Tseng HC. et al. Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. JAMA Intern Med 2019; 179: 633-640
• 118 Simon TG, Duberg AS, Aleman S. et al. Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. N Engl J Med 2020; 382: 1018-1028
• 119 Bravi F, Bosetti C, Tavani A. et al. Coffee Reduces Risk for Hepatocellular Carcinoma: An Updated Meta-analysis. Clinical Gastroenterology and Hepatology 2013; 11: 1413-1421.e1411
• 120 Bamia C, Lagiou P, Jenab M. et al. Coffee, tea and decaffeinated coffee in relation to hepatocellular carcinoma in a European population: multicentre, prospective cohort study. Int J Cancer 2015; 136: 1899-1908
• 121 Chang KC, Wang JH, Chen CH. et al. Tenofovir reduce risk of hepatocellular carcinoma development higher than entecavir in chronic hepatitis B patients with liver cirrhosis.. Hepatology 2019; 70: 313A-314A
• 122 Dave S, Murad MH, Barnard A. et al. A systematic review and network meta-analysis comparing the effects of nucleos(t)ide analogues on incidence of hepatocellular carcinoma in patients with chronic hepatitis B.. Hepatology 2019; 70: 291A-292A
• 123 Lee CJ, Lin HC, Hou MC. et al. Occurrence of hepatocellular carcinoma in chronic hepatitis B patients undergoing entecavir or tenofovir treatment.. Hepatology 2019; 70: 578A-579A
• 124 Yip TC-F, Wong VW-S, Chan HL-Y. et al. Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. Gastroenterology 2020; 158: 215-225.e216
• 125 Mangia A, Milligan S, Khalili M. et al. GS-03-Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: Integrated analysis of 12 clinical practice cohorts. Journal of Hepatology 2019; 70: e2-e3
• 126 Chahal HS, Marseille EA, Tice JA. et al. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. JAMA Internal Medicine 2016; 176: 65
• 127 Zhang B-H, Yang B-H, Tang Z-Y. Randomized controlled trial of screening for hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology 2004; 130
• 128 Poustchi H, Farrell GC, Strasser SI. et al. Feasibility of conducting a randomized control trial for liver cancer screening: Is a randomized controlled trial for liver cancer screening feasible or still needed?. Hepatology 2011; 54: 1998-2004
• 129 Singal A, Volk ML, Waljee A. et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Alimentary pharmacology & therapeutics 2009; 30: 37-47
• 130 Santi V, Trevisani F, Gramenzi A. et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. Journal of Hepatology 2010; 53: 291-297
• 131 Trinchet J-C, Chaffaut C, Bourcier V. et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3- and 6-month periodicities. Hepatology 2011; 54: 1987-1997
• 132 Andersson KL, Salomon JA, Goldie SJ. et al. Cost Effectiveness of Alternative Surveillance Strategies for Hepatocellular Carcinoma in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology 2008; 6: 1418-1424
• 133 Huang G, Lau WY, Wang ZG. et al. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. Ann Surg 2015; 261: 56-66
• 134 Mashiba T, Joko K, Kurosaki M. et al. Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group. PLoS One 2018; 13: e0194704
• 135 Beste LA, Green PK, Berry K. et al. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. J Hepatol 2017; 67: 32-39
• 136 Conti F, Buonfiglioli F, Scuteri A. et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016; 65: 727-733
• 137 Reig M, Marino Z, Perello C. et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016; 65: 719-726
• 138 Lleo A, Aglitti A, Aghemo A. et al. Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. Dig Liver Dis 2019; 51: 310-317
• 139 Ide T, Koga H, Nakano M. et al. Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study. Hepatol Int 2019; 13: 293-301
• 140 Singal AG, Lim JK, Kanwal F. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review. Gastroenterology 2019; 156: 2149-2157
• 141 Zhang K, Chen R, Gong X. et al. Survival outcomes of liver transplantation versus liver resection among patients with hepatocellular carcinoma: A SEER-based longitudinal study. J Formos Med Assoc 2019; 118: 790-796
• 142 Shen JY, Li C, Wen TF. et al. Liver transplantation versus surgical resection for HCC meeting the Milan criteria: A propensity score analysis. Medicine (Baltimore) 2016; 95: e5756
• 143 Menahem B, Lubrano J, Duvoux C. et al. Liver transplantation versus liver resection for hepatocellular carcinoma in intention to treat: An attempt to perform an ideal meta-analysis. Liver Transpl 2017; 23: 836-844
• 144 Lee WC, Lee CF, Cheng CH. et al. Outcomes of liver resection for hepatocellular carcinoma in liver transplantation era. Eur J Surg Oncol 2015; 41: 1144-1152
• 145 Proneth A, Zeman F, Schlitt HJ. et al. Is resection or transplantation the ideal treatment in patients with hepatocellular carcinoma in cirrhosis if both are possible? A systematic review and metaanalysis. Ann Surg Oncol 2014; 21: 3096-3107
• 146 Lynch SM, Vrieling A, Lubin JH. et al. Cigarette Smoking and Pancreatic Cancer: A Pooled Analysis From the Pancreatic Cancer Cohort Consortium. American Journal of Epidemiology 2009; 170: 403-413
• 147 Vrieling A, Bueno-de-Mesquita HB, Boshuizen HC. et al. Cigarette smoking, environmental tobacco smoke exposure and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2010; 126: 2394-2403
• 148 Doll R, Peto R, Wheatley K. et al. Mortality in relation to smoking: 40 years’ observations on male British doctors. BMJ 1994; 309: 901-911
• 149 Han S, Kheder J, Bocelli L. et al. Smoking Cessation in a Chronic Pancreatitis Population. Pancreas 2016; 45: 1303-1308
• 150 Arslan AA, Helzlsouer KJ, Kooperberg C. et al. Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch Intern Med 2010; 170: 791-802
• 151 Stolzenberg-Solomon RZ. Prospective Study of Diet and Pancreatic Cancer in Male Smokers. American Journal of Epidemiology 2002; 155: 783-792
• 152 Feakins RM. Obesity and metabolic syndrome: pathological effects on the gastrointestinal tract. Histopathology 2016; 68: 630-640
• 153 Behrens G, Jochem C, Schmid D. et al. Physical activity and risk of pancreatic cancer: a systematic review and meta-analysis. European Journal of Epidemiology 2015; 30: 279-298
• 154 Zheng W, Lee S-A. Well-Done Meat Intake, Heterocyclic Amine Exposure, and Cancer Risk. Nutrition and Cancer 2009; 61: 437-446
• 155 Wang Y-T, Gou Y-W, Jin W-W. et al. Association between alcohol intake and the risk of pancreatic cancer: a dose–response meta-analysis of cohort studies. BMC Cancer 2016; 16: 212
• 156 Seufferlein T, Porzner M, Becker T. et al. S3-guideline exocrine pancreatic cancer. Z Gastroenterol 2013; 51: 1395-1440
• 157 Kamisawa T, Wood LD, Itoi T. et al. Pancreatic cancer. Lancet 2016; 388: 73-85
• 158 Canto MI, Harinck F, Hruban RH. et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013; 62: 339-347
• 159 Klein AP, Brune KA, Petersen GM. et al. Prospective Risk of Pancreatic Cancer in Familial Pancreatic Cancer Kindreds. Cancer Research 2004; 64: 2634-2638
• 160 Landi S. Genetic predisposition and environmental risk factors to pancreatic cancer: A review of the literature. Mutat Res 2009; 681: 299-307
• 161 Lo W, Morris MC, Ahmad SA. et al. Screening patients at high risk for pancreatic cancer-Is it time for a paradigm shift?. J Surg Oncol 2019; 120: 851-857
• 162 Landi S. Genetic predisposition and environmental risk factors to pancreatic cancer: A review of the literature. Mutation Research/Reviews in Mutation Research 2009; 681: 299-307
• 163 Aslanian HR, Lee JH, Canto MI. AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review. Gastroenterology 2020; 159: 358-362
• 164 Goggins M, Overbeek KA, Brand R. et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 2020; 69: 7-17
• 165 Wolpin BM, Kraft P, Gross M. et al. Pancreatic Cancer Risk and ABO Blood Group Alleles: Results from the Pancreatic Cancer Cohort Consortium. Cancer Research 2010; 70: 1015-1023
• 166 Amundadottir L, Kraft P, Stolzenberg-Solomon RZ. et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nature Genetics 2009; 41: 986-990
• 167 Canto MI, Almario JA, Schulick RD. et al. Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Gastroenterology 2018; 155: 740-751 e742
• 168 Lowenfels AB, Maisonneuve P, Cavallini G. et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993; 328: 1433-1437
• 169 Kirkegard J, Mortensen FV, Cronin-Fenton D. Chronic Pancreatitis and Pancreatic Cancer Risk: A Systematic Review and Meta-analysis. Am J Gastroenterol 2017; 112: 1366-1372
• 170 Raimondi S, Lowenfels AB, Morselli-Labate AM. et al. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Practice & Research Clinical Gastroenterology 2010; 24: 349-358
• 171 McWilliams RR, Petersen GM, Rabe KG. et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and risk for pancreatic adenocarcinoma. Cancer 2010; 116: 203-209
• 172 Bartsch DK, Gress TM, Langer P. Familial pancreatic cancer—current knowledge. Nature Reviews Gastroenterology & Hepatology 2012; 9: 445-453
• 173 Howes N, Lerch MM, Greenhalf W. et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol 2004; 2: 252-261
• 174 Li D, Yeung SCJ, Hassan MM. et al. Antidiabetic Therapies Affect Risk of Pancreatic Cancer. Gastroenterology 2009; 137: 482-488
• 175 Batabyal P, Vander Hoorn S, Christophi C. et al. Association of Diabetes Mellitus and Pancreatic Adenocarcinoma: A Meta-Analysis of 88 Studies. Annals of Surgical Oncology 2014; 21: 2453-2462
• 176 Sah RP, Nagpal SJ, Mukhopadhyay D. et al. New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol 2013; 10: 423-433
• 177 Soranna D, Scotti L, Zambon A. et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 2012; 17: 813-822
• 178 Lee DY, Yu JH, Park S. et al. The influence of diabetes and antidiabetic medications on the risk of pancreatic cancer: a nationwide population-based study in Korea. Scientific Reports 2018; 8: 9719
• 179 Colmers IN, Bowker SL, Tjosvold LA. et al. Insulin use and cancer risk in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies. Diabetes & Metabolism 2012; 38: 485-506
• 180 Sharma A, Chari ST. Pancreatic Cancer and Diabetes Mellitus. Current Treatment Options in Gastroenterology 2018; 16: 466-478
• 181 Koch-Institut. ZfKiR. Bericht zum Krebsgeschehen in Deutschland 2016. 2016; 274
• 182 Vuik FER, Nieuwenburg SAV, Bardou M. et al. Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut 2019; 68: 1820-1826
• 183 Siegel RL, Fedewa SA, Anderson WF. et al. Colorectal Cancer Incidence Patterns in the United States, 1974–2013. JNCI: Journal of the National Cancer Institute 2017; 109
• 184 Troeung L, Sodhi-Berry N, Martini A. et al. Increasing Incidence of Colorectal Cancer in Adolescents and Young Adults Aged 15–39 Years in Western Australia 1982–2007: Examination of Colonoscopy History. Frontiers in Public Health 2017; 5: 179
• 185 Patel P, De P. Trends in colorectal cancer incidence and related lifestyle risk factors in 15–49-year-olds in Canada, 1969–2010. Cancer Epidemiology 2016; 42: 90-100
• 186 Botteri E, Iodice S, Bagnardi V. et al. Smoking and Colorectal Cancer: A Meta-analysis. JAMA 2008; 300: 2765
• 187 Cai S, Li Y, Ding Y. et al. Alcohol drinking and the risk of colorectal cancer death: a meta-analysis. European Journal of Cancer Prevention 2014; 23: 532-539
• 188 Wolin KY, Yan Y, Colditz GA. Physical activity and risk of colon adenoma: a meta-analysis. British Journal of Cancer 2011; 104: 882-885
• 189 Kyrgiou M, Kalliala I, Markozannes G. et al. Adiposity and cancer at major anatomical sites: umbrella review of the literature. BMJ 2017; 356: j477
• 190 Chan DSM, Lau R, Aune D. et al. Red and Processed Meat and Colorectal Cancer Incidence: Meta-Analysis of Prospective Studies. PLoS ONE 2011; 6: e20456
• 191 Dahm CC, Keogh RH, Spencer EA. et al. Dietary Fiber and Colorectal Cancer Risk: A Nested Case-Control Study Using Food Diaries. JNCI Journal of the National Cancer Institute 2010; 102: 614-626
• 192 Park Y, Hunter DJ, Spiegelman D. et al. Dietary Fiber Intake and Risk of Colorectal Cancer: A Pooled Analysis of Prospective Cohort Studies. JAMA 2005; 294: 2849
• 193 Krämer HU, Schöttker B, Raum E. et al. Type 2 diabetes mellitus and colorectal cancer: Meta-analysis on sex-specific differences. European Journal of Cancer 2012; 48: 1269-1282
• 194 Guraya SY. Association of type 2 diabetes mellitus and the risk of colorectal cancer: A meta-analysis and systematic review. World Journal of Gastroenterology 2015; 21: 6026-6031
• 195 Song M, Garrett WS, Chan AT. Nutrients, Foods, and Colorectal Cancer Prevention. Gastroenterology 2015; 148: 1244-1260.e1216
• 196 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF). S3-Leitlinie Kolorektales Karzinom. In: 2019:. https://www.dgvs.de/wp-content/uploads/2019/01/LL_KRK_Langversion_2.1.pdf
• 197 Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. The Lancet Oncology 2012; 13: 518-527
• 198 Bibbins-Domingo K, on behalf of the USPSTF. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine 2016; 164: 836
• 199 Dekker E, Tanis PJ, Vleugels JLA. et al. Colorectal cancer. The Lancet 2019; 394: 1467-1480
• 200 Nguyen SP, Bent S, Chen Y-H. et al. Gender as a Risk Factor for Advanced Neoplasia and Colorectal Cancer: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2009; 7: 676-681.e673
• 201 Brenner H, Chang-Claude J, Jansen L. et al. Reduced Risk of Colorectal Cancer Up to 10 Years After Screening, Surveillance, or Diagnostic Colonoscopy. Gastroenterology 2014; 146: 709-717
• 202 Pox CP, Altenhofen L, Brenner H. et al. Efficacy of a Nationwide Screening Colonoscopy Program for Colorectal Cancer. Gastroenterology 2012; 142: 1460-1467.e1462
• 203 Zhu MM, Xu XT, Nie F. et al. Comparison of immunochemical and guaiac-based fecal occult blood test in screening and surveillance for advanced colorectal neoplasms: A meta-analysis: Screening for colorectal cancer. Journal of Digestive Diseases 2010; 11: 148-160
• 204 Labianca R, Nordlinger B, Beretta GD. et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2013; 24: vi64-vi72
• 205 Riemann JF, Maar C, Betzler M. et al. Early detection of colonic cancer in the National Cancer Program – present status and recommendations. Z Gastroenterol 2011; 49: 1428-1431
• 206 Riemann JF, Schilling D, Hüppe D. et al. Das neue Darmkrebs-Screening. Z Gastroenterol 2020; 58: 787-788
• 207 Senore C, Inadomi J, Segnan N. et al. Optimising colorectal cancer screening acceptance: a review. Gut 2015; 64: 1158-1177
• 208 Rex DK, Boland RC, Dominitz JA. et al. Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology 2017; 112: 1016-1030
• 209 Sung JJY, Lau JYW, Young GP. et al. Asia Pacific consensus recommendations for colorectal cancer screening. Gut 2008; 57: 1166-1176
• 210 Sung JJY, Ng SC, Chan FKL. et al. An updated Asia Pacific Consensus Recommendations on colorectal cancer screening. Gut 2015; 64: 121-132
• 211 Knudsen AB, Zauber AG, Rutter CM. et al. Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force. JAMA 2016; 315: 2595
• 212 Stock C, Brenner H. Utilization of lower gastrointestinal endoscopy and fecal occult blood test in 11 European countries: evidence from the Survey of Health, Aging and Retirement in Europe (SHARE). Endoscopy 2010; 42: 546-556
• 213 Zhan T, Hielscher T, Bilge A. et al. Invitation letters increase participation in colorectal cancer screening – results from an observational study. Zeitschrift für Gastroenterologie 2017; 55: 1307-1312
• 214 Cole SR, Smith A, Wilson C. et al. An advance notification letter increases participation in colorectal cancer screening. Journal of Medical Screening 2007; 14: 73-75
• 215 Ziegler M, Schubring-Giese B, Bühner M. et al. Attitude to Secondary Prevention and Concerns about Colonoscopy Are Independent Predictors of Acceptance of Screening Colonoscopy. Digestion 2010; 81: 120-126
• 216 Zhan T, Hielscher T, Eckardt M. et al. The effect of gender-specific invitation letters on utilization of colorectal cancer screening. Zeitschrift für Gastroenterologie 2019; 57: 1051-1058
• 217 Baron JA, Cole BF, Sandler RS. et al. A Randomized Trial of Aspirin to Prevent Colorectal Adenomas. New England Journal of Medicine 2003; 348: 891-899
• 218 Benamouzig R, Deyra J, Martin A. et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial1 1The authors thank the women and men who participated in the study, P. E. Douziech for coordination of treatments, and the hospital pharmacists for preparation of the treatments in the trial centers. Gastroenterology 2003; 125: 328-336
• 219 Weingarten MAMA, Zalmanovici Trestioreanu A, Yaphe J. Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps. http://doi.wiley.com/10.1002/14651858.CD003548.pub4Cochrane Database of Systematic Reviews . 2008
• 220 Enblad P, Adami HO, Glimelius B. et al. The risk of subsequent primary malignant diseases after cancers of the colon and rectum. A nationwide cohort study. Cancer 1990; 65: 2091-2100
• 221 Cali RL, Pitsch RM, Thorson AG. et al. Cumulative incidence of metachronous colorectal cancer. Diseases of the Colon & Rectum 1993; 36: 388-393
• 222 Yamazaki T, Takii Y, Okamoto H. et al. What is the risk factor for metachronous colorectal carcinoma?. Diseases of the Colon & Rectum 1997; 40: 935-938
• 223 Vogl TJ, Pereira PL, Helmberger T. et al. Updated S3 Guidelines – Diagnosis and Treatment of Colorectal Carcinoma: Relevance for Radiological Diagnosis and Intervention. Rofo 2019; 191: 298-310
• 224 Cooper GS, Kou TD, Reynolds HL. Receipt of guideline-recommended follow-up in older colorectal cancer survivors: A Population-based Analysis. Cancer 2008; 113: 2029-2037
• 225 Van Blarigan EL, Fuchs CS, Niedzwiecki D. et al. Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial. JAMA Oncology 2018; 4: 783
• 226 Liao X, Lochhead P, Nishihara R. et al. Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival. New England Journal of Medicine 2012; 367: 1596-1606
• 227 Li P, Wu H, Zhang H. et al. Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis. Gut 2015; 64: 1419-1425